



# Market Announcement

30 March 2020

---

## Benitec Biopharma Limited (ASX: BLT) – Suspension from Official Quotation

### Description

The securities of Benitec Biopharma Limited ('BLT') will be suspended from quotation immediately under Listing Rule 17.2, following lodgement of the Supreme Court of Queensland orders with the Australian Securities and Investments Commission approving the scheme of arrangement by which Benitec Biopharma Inc. will acquire all of the issued shares in BLT.

### Issued by

**Corey Lian**

Adviser, Listings Compliance (Sydney)



30 March 2020

Corey Lian  
ASX Listings Compliance  
20 Bridge Street  
Sydney NSW 2000

Email: [Corey.Lian@asx.com.au](mailto:Corey.Lian@asx.com.au)

Copy: [tradinghaltssydney@asx.com.au](mailto:tradinghaltssydney@asx.com.au)

Dear Corey

### **Request for voluntary suspension**

Benitec Biopharma Limited ACN 068 943 662 (**Company**) (ASX: BLT) requests that ASX grants a voluntary suspension of its ordinary shares with effect from close of trading today.

The Company advises the following:

- the Company is requesting a suspension as the Company has lodged orders made by the Supreme Court of Queensland approving a scheme of arrangement (**Scheme**) whereby all ordinary shares in the Company will be acquired by Benitec Biopharma Inc.;
- the Company expects the suspension to last until 15 April 2020 (being the expected implementation date of the Scheme), or until such time the Scheme is implemented and the Company's shares are removed from the official list of ASX;
- the Company is not aware of any reason why the voluntary suspension should not be granted; and
- the Company considers there is no other information necessary to inform the market about the voluntary suspension.

Yours faithfully

**Benitec Biopharma Limited**

**Oliver Kidd**

Company Secretary